First Financial Bank Trust Division cut its holdings in shares of Celgene Co. (NASDAQ:CELG) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,747 shares of the biopharmaceutical company’s stock after selling 2,523 shares during the period. First Financial Bank Trust Division’s holdings in Celgene were worth $2,478,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of CELG. Thompson Davis & CO. Inc. lifted its holdings in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG bought a new position in Celgene during the third quarter worth about $114,000. Guidant Wealth Advisors bought a new position in Celgene during the third quarter worth about $119,000. Finally, Capital Bank & Trust Co lifted its holdings in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.
Shares of Celgene Co. (NASDAQ:CELG) opened at $91.02 on Friday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $71,577.03, a PE ratio of 25.42, a P/E/G ratio of 0.68 and a beta of 1.49. Celgene Co. has a 12-month low of $90.98 and a 12-month high of $147.17.
CELG has been the topic of several recent analyst reports. Royal Bank of Canada reduced their target price on Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and set a $156.00 target price on shares of Celgene in a report on Friday, October 20th. Morgan Stanley cut their price target on Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a report on Monday, October 23rd. Mizuho restated a “buy” rating and issued a $128.00 price target on shares of Celgene in a report on Sunday, February 4th. Finally, SunTrust Banks cut their price target on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $130.35.
In related news, insider Mark J. Alles bought 3,260 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares in the company, valued at $16,441,277.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is currently owned by insiders.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.